Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Eiger BioPharmaceuticals (EIGR) Stock Price
News headlines about Eiger BioPharmaceuticals (NASDAQ:EIGR) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Eiger BioPharmaceuticals earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.15756047274 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
EIGR has been the subject of several research reports. Wedbush reiterated an “outperform” rating and issued a $34.00 target price (up previously from $28.00) on shares of Eiger BioPharmaceuticals in a report on Wednesday, June 21st. BTIG Research initiated coverage on shares of Eiger BioPharmaceuticals in a report on Friday, July 14th. They issued a “buy” rating and a $32.00 target price for the company. Zacks Investment Research downgraded shares of Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 26th. ValuEngine upgraded shares of Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $34.00 target price on shares of Eiger BioPharmaceuticals in a report on Monday, September 25th. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. Eiger BioPharmaceuticals currently has a consensus rating of “Hold” and an average target price of $32.60.
Eiger BioPharmaceuticals (NASDAQ:EIGR) traded up 3.21% during mid-day trading on Friday, reaching $12.85. 101,066 shares of the company traded hands. Eiger BioPharmaceuticals has a 52-week low of $6.10 and a 52-week high of $14.75. The stock’s market capitalization is $107.52 million. The stock has a 50-day moving average of $10.10 and a 200 day moving average of $8.62.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.05). Equities research analysts expect that Eiger BioPharmaceuticals will post ($5.21) earnings per share for the current year.
In related news, Director Jeffrey S. Glenn purchased 15,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was purchased at an average price of $9.53 per share, with a total value of $142,950.00. Following the completion of the transaction, the director now owns 31,355 shares of the company’s stock, valued at approximately $298,813.15. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 28.80% of the company’s stock.
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.